More than 100 million people across the globe have been infected with COVID-19. Evidence is mounting on long-term neurological and cognitive symptoms that can persist in some COVID-19 patients, including after the virus is no longer detected in the body.
Two randomized remote studies, one conducted by Weill Cornell Medicine and NewYork-Presbyterian Hospital and the other by Vanderbilt University Medical Center, will assess whether AKL-T01, the treatment that Akili commercially markets for ADHD as EndeavorRx, can help improve cognition symptoms in Covid survivors.
